#USA #Princeton #Soligenix #HyBryte #SGX302

Overview of Soligenix

Soligenix, Inc. (Nasdaq: SNGX) is a biopharmaceutical firm specializing in the development and commercialization of innovative therapies targeting rare diseases. This company is firmly focused on addressing unmet medical needs through its diverse pipeline of products. As Soligenix releases its recent achievements and financial results for Q2 2025, it showcases progress and strategic plans for future development.

Recent Accomplishments

On August 14, 2025, Soligenix provided a comprehensive update on their recent successes, highlighting key milestones achieved by the second quarter. Company President and CEO Christopher J. Schaber, PhD, expressed optimism regarding the company's late-stage pipeline. Notable achievements include:

• - Completion of Phase 2a Trial: On July 31, 2025, the company announced the successful conclusion of its Phase 2a proof of concept study for SGX945 (dusquetide) in treating Behçet's Disease, demonstrating the biological efficacy of the treatment.

• - Clinical Developments in Psoriasis: Anticipation builds as preliminary results from the Phase 2a clinical trial with SGX302 (synthetic hypericin) for mild-to-moderate psoriasis are set to be revealed by the end of 2025.

• - Ongoing Investigator-Initiated Studies: Continuation of the investigator-initiated study evaluating extended HyBryte™ (synthetic hypericin) treatment for early-stage cutaneous T-cell lymphoma (CTCL) for up to 54 weeks.

• - Manufacturing Transfer Completed: As of July 1, 2025, the company successfully transferred the manufacturing process of its synthetic hypericin ingredient from Europe to the United States, solidifying its operational capabilities.

Financial Results

In the financial report for the quarter ended June 30, 2025, Soligenix documented the following significant figures:

• - Revenue: The company reported no revenue, consistent with minimal revenue during the same period in 2024.
• - Net Loss: The net loss for the quarter stood at $2.7 million, equating to ($0.82) per share, a notable increase from the $1.6 million net loss incurred in the same quarter last year.
• - Research & Development Expenses: R&D expenses rose to $1.7 million, up sharply from $0.5 million in Q2 2024, driven by costs associated with ongoing clinical trials and third-party manufacturing demands.
• - Administrative Expenses: General and administrative expenses slightly decreased to $1.1 million from $1.2 million in the prior year due to a reduction in professional fees.
• - Cash Position: As of the end of June 2025, Soligenix held approximately $5.1 million in cash, not including $1.4 million from its At-The-Market facility secured shortly thereafter.

Future Directions

Moving forward, Soligenix remains strategic in managing its resources while assessing various funding opportunities to support their pipeline's progression. The company is exploring potential partnerships, mergers, acquisitions, government grants, and other financing options to bolster their financial standing and accelerate the development of vital therapies.

With a rich pipeline and a number of key milestones on the horizon, Soligenix is poised to make significant strides in addressing critical healthcare challenges in the realm of rare diseases. The next few months will be crucial as the company approaches completion of ongoing trials and anticipates important data that could further validate its innovative treatment modalities.

For more information on Soligenix, Inc. and its advancements, please visit Soligenix's official website or follow them on social media platforms LinkedIn and Twitter.